BioShares and Reality Shares Make Their Debut; ValueShares Launches IVAL

By: ETFdb
This week in ETFs, two new issuers made their debut: BioShares by LifeSci Index Partners and Reality Shares. The two new BioShares funds offer investors a compelling way to make a more targeted play on the fast-growing biotechnology sector. Reality Shares’ new actively-managed ETF provides a new twist on dividend investing, focusing more on the expected growth of dividends instead of yield. Also this week, ValueShares launched the international version of its “quantitative value” fund [see also ETF Spotlight: MSCI USA Size Factor ETF (SIZE)]. More Granular Biotech Exposure On Tuesday, BioShares by LifeSci Index Partners launched two new funds that are aimed at providing investors unique exposure to the biotechnology industry. The BioShares Biotechnology Products Fund (BBP) tracks the LifeSci Biotechnology Products Index, an equal weighted benchmark that is designed to measure the equity market performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering or product candidate that has received U.S. Food and Drug Administration […] Click here to read the original article on ETFdb.com. Related Posts: No Related Posts
This week in ETFs, two new issuers made their debut: BioShares by LifeSci Index Partners and Reality Shares. The two new BioShares funds offer investors a compelling way to make a more targeted play on the fast-growing biotechnology sector. Reality Shares’ new actively-managed ETF provides a new twist on dividend investing, focusing more on the expected growth of dividends instead of yield. Also this week, ValueShares launched the international version of its “quantitative value” fund [see also ETF Spotlight: MSCI USA Size Factor ETF (SIZE)]. More Granular Biotech Exposure On Tuesday, BioShares by LifeSci Index Partners launched two new funds that are aimed at providing investors unique exposure to the biotechnology industry. The BioShares Biotechnology Products Fund (BBP) tracks the LifeSci Biotechnology Products Index, an equal weighted benchmark that is designed to measure the equity market performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering or product candidate that has received U.S. Food and Drug Administration […]

Click here to read the original article on ETFdb.com.

Related Posts:
  • No Related Posts

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.